Aegeline mitigates isoproterenol-induced myocardial infarction: insights from biochemical, histopathological, and in silico studies
Frontiers in Cardiovascular Medicine · 21.07.2026 · 13
DOI: 10.3389/fcvm.2026.1805096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 21.07.2026. Verfasst von Sami I Alzarea und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Saudi Arabia. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Although considerable advances have been made in its diagnosis and management, the development of safe and effective cardioprotective agents remains an active area of investigation. Natural products continue to attract interest as potential therapeutic candidates because of their diverse pharmacological activities. Aegeline, an alkaloidal amide isolated from Aegle marmelos , has demonstrated antioxidant and anti-inflammatory properties; however, its cardioprotective effects in experimental myocardial injury have not been fully characterized.
Objective
The aim of this work was to assess the cardioprotective effects of aegeline in an experimental MI model.
Methods
Isoproterenol (ISO) (85 mg/kg, subcutaneouslySC) was employed to trigger acute MI in experimental rats. Aegeline was administered to the rats at doses of 5 and 10 mg (p.o.) on the 29th and 30th day, respectively, followed by ISO (85 mg/kg) (s.c.) on the same days.
Results
Aegeline exhibited cardioprotective properties against ISO-induced damage, as evidenced by the amelioration of altered histopathological features, reduction in myocardial damage, and improvements in antioxidant and oxidative stress markers, inflammatory indicators, and signaling pathways, along with inhibition of apoptotic expression. In addition, aegeline did not affect liver or kidney function. Molecular docking using AutoDock Vina v1.2.6 revealed the strong binding affinity of aegeline for CK-MB (PDB ID: 3B6R), with key hydrophobic, hydrogen-bonding, and salt bridge interactions. Additional targets included LDH (7DBJ), cTnT (1J1D), and cTnI (7SC2), though CK-MB exhibited the most favorable interaction profile. Molecular dynamics simulations supported these findings through principal component analysis, dynamic cross-correlation, free energy landscape mapping, and generalized born surface area (MM-GBSA) binding free energy analysis.
Conclusion
This study demonstrates that aegeline attenuates experimental myocardial injury by reducing oxidative stress, inflammation, and apoptosis. Computational analyses support potential molecular interactions with proteins associated with myocardial injury, while the biochemical and histopathological findings provide primary evidence for its cardioprotective activity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Saudi Arabia.
- Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia.
- Division of Basic Medical Sciences, College of Medicine, Dhofar University, Salalah, Oman.
- Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Saudi Arabia.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Al-Jouf, Saudi Arabia.
Zitieren
APA
Alzarea, S. I., Afzal, M., Rafeeq, M., Habib, A. H., Alsahli, T. G., Alsaidan, O. A., Alhassan, H. H., Alzarea, A. I., Alsaidan, A. A., Sayyed, N., & Kazmi, I. (2026). Aegeline mitigates isoproterenol-induced myocardial infarction: insights from biochemical, histopathological, and in silico studies. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1805096
Vancouver
Alzarea SI, Afzal M, Rafeeq M, Habib AH, Alsahli TG, Alsaidan OA, et al. Aegeline mitigates isoproterenol-induced myocardial infarction: insights from biochemical, histopathological, and in silico studies. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1805096
BibTeX
@article{Alzarea2026,
author = {Alzarea, Sami I and Afzal, Muhammad and Rafeeq, Misbahuddin and Habib, Alaa Hamed and Alsahli, Tariq G and Alsaidan, Omar Awad and Alhassan, Hassan H and Alzarea, Abdulaziz Ibrahim and Alsaidan, Aseel Awad and Sayyed, Nadeem and Kazmi, Imran},
title = {Aegeline mitigates isoproterenol-induced myocardial infarction: insights from biochemical, histopathological, and in silico studies},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1805096}
}
EUVIMED